NBE - Therapeutics
Manufacturing · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Hochbergerstrasse Technology Parc Basel ...Phone Number
+41 616332230Website
www.nbe-therapeutics.comRevenue
$6.9 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About NBE - Therapeutics
NBE Therapeutics is dedicated to developing best-in-class oncology treatments aimed at increasing survival and improving the quality of life for cancer patients globally. Utilizing their innovative antibody-drug conjugate platform, they focus on creating targeted medicines that can effectively reduce or eradicate solid tumors. The company boasts a robust pipeline of ADC product candidates at various stages of development, reflecting their commitment to advancing cancer care. Their international team is driven by a passion for innovation and excellence in the fight against cancer.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NBE - Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
NBE - Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check if NBE - Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once NBE - Therapeutics has new funding data
Check out if NBE - Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at NBE - Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if NBE - Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when NBE - Therapeutics launches new products
Earning: See what the market has to say on NBE - Therapeutics recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined NBE - Therapeutics as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
NBE - Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
NBE - Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about NBE - Therapeutics.
NBE - Therapeutics financials insights
Gather financial insights about NBE - Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$3.1M
2016
Series B
$20.6M
2020
Series C
$22M
NBE - Therapeutics Tech Stack
A closer look at the technologies used by NBE - Therapeutics
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Mergers & Acquisitions (M&A)
Funding
Funding
Funding
NBE - Therapeutics News & Media
Merger Thursday: Gilead Buys German Drug Company, Aytu-Neos All-Stock Deal, Boehringer Picks Up NBE-Therapeutics
The day dawned as an M&A Thursday for the biotech sector, as a slew of deals of varied sizes were announced, with Gilead Sciences, Inc. (NASDAQ: GILD) and Aytu BioScience, Inc. (NASDAQ: AYTU) in the mix. read moreBoehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
INGELHEIM, Germany & BASEL, Switzerland--(BUSINESS WIRE)--Boehringer Ingelheim today announced the signing of a binding agreement for acquiring all shares of NBE-Therapeutics, a private, clinical-stage Swiss biotechnology company focused on antibody-drug conjugates and advancing targeted cancer therapies derived from its immune stimulatory iADC™ platform. NBE-Therapeutics’ lead compound NBE-002 is currently in phase I clinical studies for triple negative breast cancer and other solid tumors. ImBolstering Cancer Platform, Boehringer Acquires NBE for $1.4B USD
Pharma giant Boehringer Ingelheim strengthened its immuno-oncology portfolio this week by inking an acquisition deal with NBE Therapeutics for a tidy $1.4 billion US.NBE-Therapeutics Commences First Clinical Study of Anti-ROR1 Antibody-Drug Conjugate for Patients with Solid Tumors
BASEL, Switzerland, Oct. 26, 2020 /PRNewswire/ -- NBE-Therapeutics, a Swiss-based company developing best-in-class cancer therapies based on its proprietary, highly differentiated Antibody-Drug Conjugate (ADC) platform, today announced that it has commenced first-in-human studies of its...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding NBE - Therapeutics
Sign Up For FreeTo access detailed company insights
NBE Therapeutics is dedicated to developing best-in-class oncology treatments aimed at increasing survival and improving the quality of life for cancer patients globally. Utilizing their innovative antibody-drug conjugate platform, they focus on creating targeted medicines that can effectively reduce or eradicate solid tumors. The company boasts a... Read More
